Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Current Assets (2017 - 2025)

Serina Therapeutics (SER) has disclosed Current Assets for 9 consecutive years, with $6.1 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 7.12% to $6.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.1 million through Dec 2025, up 7.12% year-over-year, with the annual reading at $6.1 million for FY2025, 7.12% up from the prior year.
  • Current Assets hit $6.1 million in Q4 2025 for Serina Therapeutics, down from $11.5 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $11.5 million in Q3 2025 to a low of $1.1 million in Q3 2023.
  • Historically, Current Assets has averaged $4.3 million across 5 years, with a median of $2.3 million in 2021.
  • Biggest five-year swings in Current Assets: skyrocketed 560.52% in 2024 and later crashed 35.62% in 2025.
  • Year by year, Current Assets stood at $2.2 million in 2021, then increased by 9.8% to $2.5 million in 2022, then skyrocketed by 210.6% to $7.6 million in 2023, then fell by 25.5% to $5.7 million in 2024, then rose by 7.12% to $6.1 million in 2025.
  • Business Quant data shows Current Assets for SER at $6.1 million in Q4 2025, $11.5 million in Q3 2025, and $8.0 million in Q2 2025.